Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapagliflozin/Linagliptin - HK inno.N

Next Previous
X
Search
Drug Profile

Dapagliflozin/Linagliptin - HK inno.N

Alternative Names: IN-C009

Latest Information Update: 28 Jul 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HK inno.N
  • Developer HK inno.N; Korea University Anam Hospital
  • Class Alkynes; Amines; Antihyperglycaemics; Benzhydryl compounds; Chlorobenzenes; Glucosides; Heart failure therapies; Ketones; Obesity therapies; Piperidines; Purines; Pyrans; Quinazolines; Small molecules; Urologics
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 28 Jul 2023 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers, In adults) in South Korea
  • 02 Mar 2021 IN C009 is available for licensing as of 02 Mar 2021. http://www.inno-n.com/eng/index.asp
  • 02 Mar 2021 Phase-III clinical trials in Type 2 diabetes mellitus (unspecified route) before March 2021 (HK inno.N pipeline, March 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top